• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Tempus AI Inc.

    8/8/24 4:38:12 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology
    Get the next $TEM alert in real time by email
    SC 13G 1 formsc13g.htm Proof -

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

     

    Tempus AI, Inc.

    (Name of Issuer)

     

    Class A Common Stock

    (Titles of Class of Securities)

     

    71535D106

    (CUSIP Number)

     

    June 30, 2024

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐ Rule 13d-1(b)

     

    ☐ Rule 13d-1(c)

     

    ☒ Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     
     

     

    1  

    Name of Reporting Person

     

    BK TL21 LLC

    2  

    Check the Appropriate Box if a Member of a Group

    (a) ☐ (b) ☐

     

    3  

    SEC Use Only

     

    4  

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

      5  

    Sole Voting Power

     

    0

      6  

    Shared Voting Power

     

    16,560,249

      7  

    Sole Dispositive Power

     

    0

      8  

    Shared Dispositive Power

     

    16,560,249

    9  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    16,560,249

    10  

    Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares

     

    ☐

    11  

    Percent of Class Represented by Amount in Row 9

     

    11.1%1

    12  

    Type of Reporting Person

     

    CO

     

     

    1 Based on 149,274,923 shares outstanding as reported the issuer’s Form 10-Q for the quarterly period ended June 30, 2024 filed with the SEC on August 6, 2024.

     

     
     

     

    1  

    Name of Reporting Person

     

    Bradley Keywell

    2  

    Check the Appropriate Box if a Member of a Group

    (a) ☐ (b) ☐

     

    3  

    SEC Use Only

     

    4  

    Citizenship or Place of Organization

     

    United States

    Number of

    Shares Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

      5  

    Sole Voting Power

     

    16,560,249

      6  

    Shared Voting Power

     

    0

      7  

    Sole Dispositive Power

     

    0

      8  

    Shared Dispositive Power

     

    16,560,249

    9  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    16,560,249

    10  

    Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares

     

    ☐

    11  

    Percent of Class Represented by Amount in Row 9

     

    11.1%2

    12  

    Type of Reporting Person

     

    IN

     

     

    2 Based on 149,274,923 shares outstanding as reported the issuer’s Form 10-Q for the quarterly period ended June 30, 2024 filed with the SEC on August 6, 2024.

     

     
     

     

    Item 1(a). Name of Issuer:

     

    Tempus AI, Inc.

     

    Item 1(b). Address of Issuer’s Principal Executive Offices:

     

    600 West Chicago Avenue, Suite 510

     

    Chicago, Illinois 60654

     

    Item 2(a). Name of Person Filing:

     

    This Schedule 13G is being filed by the following persons (each, a “Reporting Person”):

     

    i. BK TL21 LLC (“BK”)

     

    ii. Bradley Keywell (“Keywell”)

     

    Item 2(b). Address of Principal Business Office or, if none, Residence:

     

    The principal business address of each of the Reporting Persons is:

     

    4603 Franklin Pike

     

    Nashville, Tennessee 37220

     

    Item 2(c). Citizenship:

     

    BK is organized under the laws of the State of Delaware.

     

    Keywell is a citizen of the United States.

     

    Item 2(d). Titles of Classes of Securities:

     

    Class A Common Stock, par value $0.0001 per share (the “Shares”).

     

    Item 2(e). CUSIP Number:

     

    71535D106

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    Not applicable.

     

    Item 4. Ownership

     

    (a) Amount beneficially owned:

     

    See response to Item 9 on each Reporting Person’s cover page.

     

    (b) Percent of class:

     

    See response to Item 11 on Reporting Person’s cover page.

     

    (c) Number of shares as to which such person has:

     

    (i) Sole power to vote or to direct the vote:

     

    See response to Item 5 on each Reporting Person’s cover page.

     

     
     

     

    (ii) Shared power to vote or to direct the vote:

     

    See response to Item 6 on each Reporting Person’s cover page.

     

    (iii) Sole power to dispose or to direct the disposition of:

     

    See response to Item 7 on each Reporting Person’s cover page.

     

    (iv) Shared power to dispose or to direct the disposition of:

     

    See response to Item 8 on each Reporting Person’s cover page.

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    Not applicable.

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10. Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a–11.

     

     
     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: August 8, 2024

     

      BK TL21 LLC.
         
      By: /s/ Bradley Keywell
      Name:  Bradley Keywell
      Title: Manager

     

      /s/ Bradley Keywell
      Bradley Keywell

     

     

     

    Get the next $TEM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TEM

    DatePrice TargetRatingAnalyst
    4/21/2025$60.00Buy
    BTIG Research
    2/25/2025$50.00 → $55.00Overweight → Neutral
    Analyst
    2/12/2025Outperform → Mkt Perform
    William Blair
    2/5/2025$58.00 → $74.00Buy
    TD Cowen
    12/13/2024$60.00Outperform
    Wolfe Research
    12/9/2024$74.00Buy
    Guggenheim
    11/11/2024$45.00 → $65.00Buy → Hold
    Stifel
    10/2/2024$45.00 → $60.00Buy → Neutral
    BofA Securities
    More analyst ratings

    $TEM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Introducing Tempus One in the EHR with Integrated Guidelines

      The AI-enabled clinical assistant is available to query patient data across the EHR as well as build custom agents to maximize workflow Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the expansion of Tempus One—its generative AI clinical assistant—with direct integration into electronic health record (EHR) systems. By integrating AI at every point of the clinical care process, the expanded capabilities of Tempus One offer physicians in oncology and beyond more support in treatment decisions. Tempus One is uniquely positioned to offer these new features given the company's depth and scale of EHR

      6/1/25 8:30:00 AM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology
    • Tempus Introduces Fuses, A Program Designed to Transform Therapeutic Research and Build the Largest Diagnostic Platform Using its Novel Foundation Model

      The initiative will apply its massive, multimodal dataset to build models that aim to improve diagnostic, prognostic, and predictive modeling Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the launch of its Fuses program. This initiative will harness Tempus' proprietary dataset to generate valuable insights for both patient care and research, combining the power of its data and machine learning capabilities to develop an AI enabled-diagnostic platform offering physicians the largest suite of algorithmic tests designed to make precision medicine a reality. Over the past decade, Tempus has built

      5/31/25 8:30:00 AM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology
    • Real-World Deployments Signal AI Healthcare Is Ready for Scale

      Equity Insider News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, May 30, 2025 /PRNewswire/ -- The concept of AI in healthcare is no longer a novelty, experts are acknowledging AI algorithms, detection, and drug discovery are becoming indispensable tools. As medical errors continue to harm patients, healthcare experts are turning to AI to improve mistakes in medications, such as prescribing the wrong drug or wrong dose. As real-world deployment gains momentum, a number of tech and biotech firms are already translating AI healthcare innovation into clinical practice. Notable recent activity includes initiatives from Avant Technologies, Inc. (OTCQB:AVAI), Tempus AI, Inc

      5/30/25 9:02:00 AM ET
      $BTAI
      $TEM
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Computer Software: Programming Data Processing
      Technology

    $TEM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Tempus AI Inc.

      SC 13G - Tempus AI, Inc. (0001717115) (Subject)

      11/12/24 5:00:02 PM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology
    • SEC Form SC 13G filed by Tempus AI Inc.

      SC 13G - Tempus AI, Inc. (0001717115) (Subject)

      11/12/24 4:30:28 PM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology
    • Amendment: SEC Form SC 13D/A filed by Tempus AI Inc.

      SC 13D/A - Tempus AI, Inc. (0001717115) (Filed by)

      8/20/24 4:27:51 PM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology

    $TEM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $TEM
    SEC Filings

    See more
    • BTIG Research initiated coverage on Tempus AI with a new price target

      BTIG Research initiated coverage of Tempus AI with a rating of Buy and set a new price target of $60.00

      4/21/25 8:39:11 AM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology
    • Tempus AI downgraded by Analyst with a new price target

      Analyst downgraded Tempus AI from Overweight to Neutral and set a new price target of $55.00 from $50.00 previously

      2/25/25 7:14:46 AM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology
    • Tempus AI downgraded by William Blair

      William Blair downgraded Tempus AI from Outperform to Mkt Perform

      2/12/25 7:11:34 AM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology
    • SEC Form 8-K filed by Tempus AI Inc.

      8-K - Tempus AI, Inc. (0001717115) (Filer)

      5/23/25 6:31:57 AM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology
    • SEC Form 144 filed by Tempus AI Inc.

      144 - Tempus AI, Inc. (0001717115) (Subject)

      5/21/25 7:23:49 PM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology
    • SEC Form 144 filed by Tempus AI Inc.

      144 - Tempus AI, Inc. (0001717115) (Subject)

      5/21/25 7:20:13 PM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology

    $TEM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Tempus Ai, Inc. exercised 9,218,800 in-the-money shares at a strike of $2.00 and bought $17,745,000 worth of shares (3,500,000 units at $5.07) (SEC Form 4)

      4 - Tempus AI, Inc. (0001717115) (Reporting)

      8/20/24 4:17:55 PM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology

    $TEM
    Financials

    Live finance-specific insights

    See more
    • Tempus Reports First Quarter 2025 Results

      Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter ended March 31, 2025. Revenue increased 75.4% year-over-year to $255.7 million in the first quarter of 2025 Quarterly gross profit increased 99.8% year-over-year, reaching $155.2 million with continued gross margin improvement in both Genomics and Data and services Announced multi-year, strategic collaborations with AstraZeneca and Pathos to work together to build the largest multimodal foundation model in oncology, resulting in additional $200.0 million in data licensing and model development fees over the next

      5/6/25 4:01:00 PM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology
    • Tempus to Report First Quarter 2025 Financial Results on May 6

      Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the first quarter of 2025 on Tuesday, May 6, 2025. The company will hold the earnings conference call at 4:30 p.m. ET. The company's quarterly earnings will be released the same day. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the events page of Tempus' Investor Relations website. Alternatively, the call can be accessed via the following: Conference ID: 4680302 Domestic Dial-in Number: (800) 715-9871 International Dial-in Number: (646) 307

      4/24/25 8:30:00 AM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology
    • Tempus to Report Fourth Quarter and Full Year 2024 Financial Results on February 24

      Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the fourth quarter and full year 2024 on Monday, February 24, 2025. The company will hold the earnings conference call at 4:30 p.m. ET. The company's quarterly earnings will be released the same day. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the events page of Tempus' Investor Relations website. Alternatively, the call can be accessed via the following: Conference ID: 9601821 Domestic Dial-in Number: (888) 596-4144 International Dial-i

      2/11/25 8:30:00 AM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology

    $TEM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Gottlieb Scott was granted 1,997 units of Class A Comnmon Stock, increasing direct ownership by 6% to 34,836 units (SEC Form 4)

      4 - Tempus AI, Inc. (0001717115) (Issuer)

      5/22/25 8:00:28 PM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology
    • Director West Nadja was granted 1,997 units of Class A Comnmon Stock, increasing direct ownership by 7% to 32,068 units (SEC Form 4)

      4 - Tempus AI, Inc. (0001717115) (Issuer)

      5/22/25 8:00:32 PM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology
    • Director Leonsis Theodore was granted 1,997 units of Class A Comnmon Stock, increasing direct ownership by 15% to 15,511 units (SEC Form 4)

      4 - Tempus AI, Inc. (0001717115) (Issuer)

      5/22/25 8:00:30 PM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology